Federal Policy Shift Allows Compounding of Six Peptides, Opening New Market for Texas Peptide Companies

A new federal policy published in the Federal Register is set to reshape the peptide sector by allowing licensed pharmacies and physicians to compound six previously restricted peptides under specified conditions. According to an Oct. 28 Reuters report by Sneha S K, with additional reporting by Kamal Choudhury and Siddhi Mahatole, the policy permits compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax without Food and Drug Administration enforcement action, provided compounders meet requirements for ingredient quality, manufacturing standards, safety reporting, labeling and patient-specific prescriptions.

The development is significant for Texas, where companies like Adaptogenics (CSE: ADPT) are building science-led operations focused on peptide and small molecule programs. The policy follows a July FDA advisory committee recommendation to permit compounding of the six peptides, despite agency scientists raising concerns about insufficient safety and effectiveness data. Health and Human Services officials said the approach could reduce reliance on potentially unsafe research-use-only peptides imported from foreign manufacturers while improving patient access.

Analysts estimate the peptide market could reach $2 billion to $3 billion if legitimized, a figure that underscores the economic stakes for Texas businesses and investors. Industry representatives welcomed the decision, although critics warned of potential contamination, impurities and unknown side effects. The policy does not constitute FDA approval of the peptides and could be reconsidered if safety or quality concerns emerge.

For Adaptogenics Health Corp., the regulatory shift adds a new dimension to the evolving market environment. The company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. It will continue its existing nutraceutical operations while evaluating GLP-1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function. The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT.

The announcement was disseminated through BioMedWire, a communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The story was edited by Shilpi Majumdar, Maju Samuel, Vijay Kishore, Caroline Humer and Leroy Leo.